Edition:
United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

44.16USD
26 Jul 2016
Change (% chg)

-- (--)
Prev Close
$44.16
Open
--
Day's High
--
Day's Low
--
Volume
2,100
Avg. Vol
3,457,899
52-wk High
$44.85
52-wk Low
$36.71

Select another date:
Photo

GlaxoSmithKline invests $360 million in UK despite Brexit vote

LONDON GlaxoSmithKline plans 275 million pounds ($361 million) of new investments at three drug manufacturing sites in Britain, signaling its confidence in the country despite last month's vote to leave the European Union.

UPDATE 3-GlaxoSmithKline invests $360 mln in UK despite Brexit vote

* UK accounts for nearly half GSK R&D, third manufacturing (Adds proportion of GSK manufacturing and R&D carried out in UK)

GlaxoSmithKline invests $360 mln in post-Brexit UK manufacturing

LONDON, July 27 GlaxoSmithKline plans 275 million pounds ($361 million) of new investments at three drug manufacturing sites in Britain, signalling its confidence in the country despite last month's vote to leave the European Union. (Reporting by Ben Hirschler; Editing by David Holmes)

BRIEF-GlaxoSmithKline ships 2016-17 seasonal influenza vaccines for US market

* GSK ships 2016-17 seasonal influenza vaccines for US market

Novartis in no rush to sell down stake on GSK consumer venture

Novartis is happy with the performance of its consumer health joint venture with GlaxoSmithKline , in which the Swiss drugmaker has a minority stake, and is in no rush to exit the collaboration early, its chief executive said.

China approves use of GSK vaccine Cervarix for cervical cancer

HONG KONG Drugmaker GlaxoSmithKline Plc said on Monday the China Food and Drug Administration (CFDA) has approved its human papillomavirus (HPV) vaccine, Cervarix, for use in the country to help women fight cervical cancer.

China approves use of GSK vaccine Cervarix for cervical cancer

HONG KONG, July 18 Drugmaker GlaxoSmithKline Plc said on Monday the China Food and Drug Administration (CFDA) has approved its human papillomavirus (HPV) vaccine, Cervarix, for use in the country to help women fight cervical cancer.

BRIEF-Mylan launches generic version of GSK's avodart capsules

* U.S. launch of Dutasteride capsules, 0.5 mg, generic version of GlaxoSmithKline's avodart capsules Source text for Eikon: Further company coverage:

BRIEF-Glaxosmithkline says though the eu referendum result creates uncertainty and potentially complexity ... It does not currently anticipate a material adverse impact on the business, group's results or financial position

* Glaxosmithkline says though the eu referendum result creates uncertainty and potentially complexity ... It does not currently anticipate a material adverse impact on the business, group's results or financial position Source text for Eikon: Further company coverage:

GAVI alliance offers matched funds for GSK malaria vaccine pilot

LONDON, June 23 The GAVI global vaccine alliance has offered funding of up to $27.5 million for pilot tests of GlaxoSmithKline's first-generation malaria vaccine, but only if other organisations promise to match that commitment.

Select another date: